NearWave Optical Molecular Monitoring

The purpose of this study is to assess the feasibility of the NearWave optical molecular monitoring system for monitoring therapy progression and predicting pathologic complete response (pCR) of breast cancer patients undergoing neoadjuvant chemotherapy (NAC).

Trial Details

NCT ID
NCT06744465
Phase
NA
Sponsor
Indiana University
Status
RECRUITING
Cancer Type
HER2 Positive Breast Cancer
Interventions
  • NearWave monitoring
Locations (sample)
  • Indianapolis, Indiana, United States|39.76838,-86.15804

Key Eligibility Criteria

  • Women ≥ 18 years old at the time of informed consent
  • Ability to provide written informed consent and HIPAA authorization
  • Patients who:
  • have been diagnosed with invasive breast cancer by tissue biopsy and have not yet started any therapy for the disease; a) Subtype HER2 positive (IH…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Positive Breast Cancer Trials on Trialify →